Biosimilar Patent Thicketing Has Cost US $7.6bn
Executive Summary
A recent study by the AAM’s Biosimilars Council has found that delayed access to biosimilars has cost the US healthcare system $7.6bn since 2015; meanwhile, Medicare has foregone more than $1.2bn in savings from biosimilars since 2015.
You may also be interested in...
AAM Urges Action On Product Hopping And Patent Thickets
The AAM’s senior vice-president, Jeffrey Francer, has offered suggestions to US lawmakers on how to curb anti-competitive tactics used by originators.
‘Perverse’ Tactics Cost US $10bn In Biosimilar Savings
The AAM’s Biosimilars Council has said “rebate traps” and other barriers to biosimilar adoption have cost the US healthcare system $2.2bn in lost savings since 2015. That’s on top of patent abuses which the council calculated in a June report have cost the healthcare system $7.6bn – bringing total lost savings from biosimilars to nearly $10bn.
Bruised Over Humira Patent Games, AbbVie Sees Smoother Road With Botox
AbbVie’s proposed acquisition of Allergan unites two companies that have gained notoriety for their exhaustive and unconventional efforts, respectively, to extend the patents of key products.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
